News

New US contracts cool conflict
Enlarge image

BusinessDenmark

New US contracts cool conflict

15.11.2012 - Despite an ongoing dispute, the US government has signed two new contracts with Danish vaccine developer Bavarian Nordic.

The Danish drugmaker announced the closing of two new contracts with the U.S. Department of Homeland Security (DHS) and the National Institutes of Health (NIH). The contracts were valued at up to US$18.9m for the development of recombinant Modified Vaccinia virus Ankara (MVA) vaccines.

The NIH contract, valued at up to US$17.9m, supports the advanced development of an MVA-based human vaccine against the viral haemorrhagic fever Marburg. The DHS contract, valued at nearly US$1m, supports the development of an MVA-based animal vaccine against Foot-and-mouth disease. "These new contracts demonstrate the versatility of our MVA platform for infectious disease vaccines and cancer immunotherapeutics," said Anders Hedegaard, President and CEO of Bavarian Nordic A/S.

Bavarian Nordic is currently in an argument with the US government. Denmark's biggest drugmaker accuses its customer not to fulfil the conditions of a 2007 contract worth US$500m. The government had promised to order 20 million doses of a smallpox vaccine that has less side effects than common ones. As Bloomberg noted, the biotech company had said in August that it would have to shed hundreds of jobs and shut down a plant if the U.S. government didn't order more of the vaccine until January.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/new-us-contracts-cool-conflict.html

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.07 CHF16.67%
  • EUROFINS SCIENTIFIC (F)283.68 EUR11.25%
  • MEDIGENE (D)9.35 EUR10.65%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.00%
  • NORDIC NANOVECTOR (N)24.40 NOK-9.29%
  • EVOTEC (D)3.33 EUR-6.20%

TOP

  • DBV Technologies (F)55.76 EUR30.3%
  • VERONA PHARMA (UK)5.20 GBP19.5%
  • BIOINVENT INTERNATIONAL AB (S)2.61 SEK15.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)24.40 NOK-29.1%
  • TRANSGENE (F)3.75 EUR-27.9%

TOP

  • ADOCIA (F)69.25 EUR409.9%
  • 4SC (D)4.88 EUR373.8%
  • VERONA PHARMA (UK)5.20 GBP322.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.20 SEK-69.4%
  • NEOVACS (F)1.13 EUR-69.4%

No liability assumed, Date: 02.07.2015